Noah announced FDA approval for its Galaxy robotic system in March.

Noah Medical, a medical robotics company, has raised $150 million in Series B funding to expand the adoption of their Galaxy System and accelerate research and development for non-invasive platforms for patient diagnosis and treatment.

The Galaxy System from Noah is a next-generation integrated solution for navigated robotic bronchoscopy, which aims to improve location accuracy and diagnosis of lung nodules.

The majority of potentially cancerous lesions are located in the outer third of the lung, which is more difficult for doctors to reach for biopsy. Current technologies are limited in their ability to both reach and then precisely target these suspect lesions. The Noah Galaxy System’s advanced imaging technologies provide real-time location updates, and are designed to improve tool-in-lesion and diagnostic yield.

The platform has already received FDA clearance for commercial use in the US and has initiated first-in-human trials in Australia.

“The Galaxy System, which features TiLT+Technology™ with integrated tomosynthesis and augmented fluoroscopy, a single-use disposable bronchoscope, and a small, compact footprint to allow for improved procedural workflow, is poised to disrupt the lung biopsy market,” Noah said in a statement.

The funding round was led by the Softbank Vision Fund and co-led by the Prosperity7 Ventures, with participation from Tiger Global and existing investors.

Related Story: Australian Agtech SwarmFarm Robotics Raises A$12M